- Chardan’s 5th Annual
Genetic Medicines Conference ,October 4 - 5, 2021 - Members of uniQure’s management team, including
Matt Kapusta , chief executive officer, will participate in virtual one-on-one investor meetings the morning ofTuesday, October 5 th. - A fireside chat with
Matt Kapusta will take place the same day from8:00 to 8:30 a.m. ET . The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
- Members of uniQure’s management team, including
Alliance for Regenerative Medicine : Cell & Gene Meeting on the Mesa,October 12 - 14, 2021 Joshua Leeman , Ph.D., VP, Search & Evaluation, Business Development, will be making a corporate presentation onWednesday, October 13 th at12:15 p.m. PDT .Dr. Leeman will also be participating in a panel entitled, “Delivering the Innovation of Gene Therapy to Patients Through Strategic Collaborations Workshop” onThursday, October 14 th starting at7:15 a.m. PDT .
European Society of Gene andCell Therapy (ESGCT),October 19 – 22. 2021- uniQure will present multiple preclinical data presentations at the meeting. Specific details to follow when the meeting abstracts are released.
- uniQure will present multiple preclinical data presentations at the meeting. Specific details to follow when the meeting abstracts are released.
- Jefferies Gene Therapy/Editing Summit,
October 27 - 28, 2021 - Members of uniQure’s management team including
Ricardo Dolmetsch , Ph.D., president of Research & Development, will participate virtually in one-on-one investor meetings throughout the day onThursday, October 28 th. - A fireside chat with
Matt Kapusta will take place the same day from12:00 to 12:30 p.m. ET . The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
- Members of uniQure’s management team including
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and
uniQure Contacts: | ||||
FOR INVESTORS: | FOR MEDIA: | |||
Direct: 339-970-7536 | Direct: 617-306-9137 | Direct: 339-970-7558 | ||
m.cantor@uniQure.com | c.russo@uniQure.com | t.malone@uniQure.com |
Source: uniQure Inc.
2021 GlobeNewswire, Inc., source